| 4 min read
Proteomic studies, billion dollar pharma deals, WHO initiatives, and more led the news this week.
| 6 min read
Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that mixture and help researchers identify the right patients for future clinical trials.
| 3 min read
Researchers showed that before cancer cells metastasize the brain, they enter a “proliferative pause” that can be targeted with drugs to prevent metastasis altogether.News
| 3 min read
John Yu built Kairos Pharma on a simple bet: Cancer drugs don't fail, tumors just learn to outrun them.
| 2 min read
Phase 2b data for EloraTZP suggest the next gains in obesity will come from stacking hormone pathways, and that tolerability may decide who wins.
| 4 min read
Pharma deals, regulatory updates, new treatments and more led the news this week.
| 3 min read
Scientists identified stem cells whose dysregulated calcium signaling drives the degenerative condition, opening the door to novel treatments.
| 4 min read
Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic.
| 4 min read
A new consortium will characterize 10,000 antibodies to a single standard, aiming to train AI models that flag manufacturing risks before candidates advance.
| 2 min read
In mice, the new drug led to recovery of motor function and vision by protecting nerve fibers and myelin.
| 2 min read
The next-generation tool, called Partita, identified both known and novel genes that contribute to resistance in lymphomas.
| 2 min read
New findings slowed tumor growth in a mouse model of triple-negative breast cancer, offering a new template for RNA drug design.
